Mizuho downgraded Adaptimmune (ADAP) to Neutral from Outperform with a 50c price target
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADAP:
- Adaptimmune’s Annual Meeting Focuses on Shareholder Engagement
- Hold Rating for Adaptimmune Therapeutics Amid Strategic Progress and Financial Uncertainties
- Biotech Alert: Searches spiking for these stocks today
- Adaptimmune’s Earnings Call: Success Amid Financial Concerns
- Cautious Hold on Adaptimmune Therapeutics Amid Strategic Developments and Liquidity Concerns